US Stock Market Today | Dow Jones | Nasdaq Live: US markets edge lower as Iran tensions weigh ahead of earnings

Intellia Therapeutics said on Monday its experimental gene-editing therapy reduced the frequency of swelling attacks in patients with a rare genetic disorder in a late-stage trial, sending its shares up more than 5% in volatile premarket trading.

The therapy lonvoguran ziclumeran ‌is aimed ⁠at treating hereditary ⁠angioedema (HAE), an inherited disorder that causes recurring episodes of swelling in the limbs, face, gastrointestinal ​tract and airways, with symptoms including abdominal pain, nausea and vomiting.

In a trial involving ​80 patients, a one-time infusion of the therapy reduced swelling episodes by 87% compared to placebo over six months, meeting the main goal.

The therapy also ​helped 62% of patients remain attack-free without regular ⁠preventive therapy ‌during that period, compared with 11% in the placebo ​group, meeting ​the secondary goal of the trial.

The company’s shares surged 30% ⁠in premarket in anticipation of positive trial data before ​paring most of those gains.